Using S100A10 as a distinct biomarker for papillary and anaplastic carcinoma would help detect these cancers in earlier stages and dramatically improve prognosis by preventing the transformation of papillary carcinoma to anaplastic carcinoma. Here, S100A10 is linked to undifferentiated carcinoma.